8 results about "CxC chemokine" patented technology

The present invention discloses a CXCL-BPI fusion protein that can be used for treating Gram-negative bacterial infections, a coding nucleic acid thereof, a method for expressing and preparing the same, and a use thereof in the manufacture of a pharmaceutical composition for treating Gram-negative bacterial infections. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a bioactive fragment of N-terminal domain of human BPI, and has the dual functions of both ELR+CXC chemokine and BPI, with ability of binding to LPS and directly killing Gram-negative bacteria, and also inducing chemotaxis and promoting phagocytes to target, bind to and phagocytize Gram-negative bacteria. The mechanism of action of the fusion protein can overcome Gram-negative bacterial drug resistance.

The application discloses a CXCL-BPI fusion protein which can be used for treating gram-negative bacterial infection, a coding nucleic acid of the CXCL-BPI fusion protein, an expression preparation method, and application of the CXCL-BPI fusion protein to preparation of a pharmaceutical composition for treating gram-negative bacterial infection. The CXCL-BPI fusion protein comprises a human ELR+CXC chemokine and a human BPI N-terminal domain functional fragment, has the functions of combining LPS, directly killing gram-negative bacteria and chemotactic cell migration, and also has the functions of promoting phagocytes to be guided to combine and phagocytize gram-negative bacteria, and the action mechanism can overcome gram-negative bacterial drug resistance.

This invention relates to the field of biological detection, and more particularly to a monoclonal antibody combination for detecting human IL-8 protein and its application. The combination comprises monoclonal antibodies 2G3 and 3H8. The heavy and light chain variable regions of monoclonal antibody 2G3 include the complementarity-determining regions shown in SEQ ID NO. 1-6; the heavy and light chain variable regions of monoclonal antibody 3H8 include the CDRs shown in SEQ ID NO. 7-12. The antibody combination of this invention exhibits high specificity and effectively avoids cross-reactivity with other CXC chemokine family members, thereby significantly reducing non-specific background interference and the risk of false positives during detection. This invention provides a high-performance, quality-controllable key tool for biological detection for non-diagnostic purposes, research on inflammatory mechanisms, and the development of related scientific reagents.

An immune response may be induced in a subject by administering to the subject a first mRNA construct encoding a homeostatic chemokine, a cytokine, or a fragment thereof, and a second antigen mRNA construct encoding an antigen. The first mRNA construct may encode a homeostatic chemokine, which is a monomeric peptide with a disulfide bridge formed by bonding between two cysteine moieties in the homeostatic chemokine. The homeostatic chemokine may be selected from the group consisting of a CXC chemokine, a CC chemokine, a CX3C chemokine, and a C chemokine. The first mRNA construct may be used as a genetic adjuvant which potentiates an immune response to a target antigen.

The invention provides application of a CXC chemokine ligand 13 as a vascular calcification diagnosis marker, and belongs to the technical field of medicines. The high expression of the CXCL13 prompts the high risk of vascular calcification, and the reagent for detecting the expression level of the CXC chemotactic factor ligand 13 can be used for preparing a vascular calcification early-warning reagent or early-warning kit. The invention studies the effect and molecular mechanism of CXCL13 in macrophages and vascular smooth muscle cells for regulating and controlling vascular calcification, provides an early intervention target for vascular calcification, and has great significance for early diagnosis and prevention of vascular calcification.

Provided herein are methods and uses of antibodies that bind to ELR+ CXC chemokines in combination with antibodies that bind to human IL-23p19 for the treatment of ulcerative colitis. Also provided are doses and dosing regimens for the methods and uses of antibodies that bind to ELR+ CXC chemokines in combination with antibodies that bind to human IL-23p19 for the treatment of ulcerative colitis.

The invention relates to a peptide comprising an amino acid sequence X6X7X8X9X10X11X12 according to SEQ ID NO: 1, or its pharmacologically acceptable salts, derivatives and / or conjugates, wherein X6 is G or A, X7 is R or A, X8 is R or A, X9 is T or A, X10 is R or A, X11 is L or A, X12 is C or A, with the proviso that one of the amino acids at position X6, X7, X8, X9, X10, X11 or X12 may be alanine, wherein the peptide has a total length in the range of 7 to 30 amino acids, and wherein a peptide consisting of the amino acid sequence KRRPAKAWSGRRTRLCC according to SEQ ID NO: 2 is excluded. The invention further relates to a medicament comprising a peptide according to SEQ ID NO: 1 and to a use for the manufacture of a medicament.

The invention provides an anti-ELR + CXC chemotactic factor antibody or an antigen binding fragment thereof as well as a preparation method and application of the anti-ELR + CXC chemotactic factor antibody. The ELR + CXC chemotactic factor antibody or the antigen binding fragment thereof. The ELR + CXC chemotactic factor is selected from one or more of CXCL1, CXCL2, CXCL3 and CXCL8. According to the application, the antibody which is specifically combined with the ELR + CXC chemotactic factor strongly related to the disease is screened out, the antibody can block a signal channel of the ELR + CXC chemotactic factor, ERK phosphorylation and human neutrophil chemotactic activity are blocked, and a new feasible scheme is provided for treatment of inflammation, immune diseases and cancers.